Products fine, but EMA still probing Roche on adverse event reporting silence
This article was originally published in SRA
The European Medicines Agency has said there are no new safety concerns for a number of Roche medicines on which the company had failed to disclose full safety data1. However, the EMA continues to pursue an infringement procedure against Roche for failing to comply with adverse event reporting requirements.
You may also be interested in...
A trio of newly finalized guidance documents from the US agency dated 25 September explain how the Accreditation Scheme for Conformity Assessment pilot will work, and what biocompatibility and safety standards will apply.
Approval of Alaway Preservative Free (ketotifen fumarate, 0.035) comes 15 months after FDA submitted a complete response letter to Bausch and the active ingredient developer, Eton Pharmaceuticals.
Unfounded expectation some firms have for FDA to protect their investments in preparing successful NDI notifications is part of industry’s overall interest in increased regulation of the market, says Steven Tave, Office of Dietary Supplement Programs director.